BioCentury | Dec 31, 2020
Distillery Therapeutics

Protease inhibitor SERPINB9 as a melanoma, breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer Inhibiting SERPINB9, a serine protease inhibitor, could treat melanoma and breast cancer. In a melanoma mouse model, tumor-specific SERPINB9 knockout reduced tumor size and the number of melanoma...
BioCentury | Oct 3, 2019

SERPINB1 and CXCR6 inhibition for multiple sclerosis

...an anti-CXCR6 mAb led to results similar to SERPINB1 knockout in the EAE mice. TARGET/MARKER/PATHWAY: Serpin family B member 1 (SERPINB1)...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 21, 2018
Preclinical News

Two algorithms could better predict response to checkpoint inhibitors

While checkpoint inhibitors have revolutionized immunotherapy, many patients don't respond to the inhibitors, and there are currently no accurate diagnostics to predict who will respond. Two papers in Nature Medicine put forth algorithms that use...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 24, 2017
Preclinical News

GWAS identify new risk loci in allergies and breast cancer

Three genome-wide association studies (GWAS) have identified new genetic markers associated with an increased risk of food allergies and breast cancer. In a paper published in Nature Communications , researchers at the Max Delbrueck Center for...
BioCentury | Dec 8, 2016
Product R&D

Unmarked territory

While the predictive power and standardization of PD-L1 diagnostics is still being hashed out by clinical immuno-oncologists, companies and academics are casting a wide net for better biomarkers to forecast patient responses to checkpoint inhibitors....
BioCentury | Oct 27, 2016
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in SERPINB3, SERPINB4 or IFNγ pathway genes could help predict responses to Yervoy ipilimumab in melanoma patients. In a cohort of 174 Yervoy -treated patients, tumor mutations in SERPINB3 or SERPINB4...
Items per page:
1 - 8 of 8